Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances AI-Driven Immunotherapy

Tevogen Bio CEO Recognized for Healthcare Leadership

Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, has been named to the NJBIZ 2025 Health Care Power List, acknowledging his contributions to healthcare innovation and accessibility in New Jersey and beyond 1

1

2

2

. This recognition comes at a time when Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, is making significant strides in AI-driven drug discovery and commercialization efforts.

Strategic Appointment to Advance Commercialization

Coinciding with Dr. Saadi's recognition, Tevogen Bio has announced the appointment of David E. Banko as Global Head of Government Affairs and Patient Access 1

1

2

2

. This strategic move is aimed at:

1. Advancing patient access
2. Engaging with public and private payers
3. Securing coding, coverage, and reimbursement pathways

These efforts are crucial components of Tevogen's commercialization strategy, supporting the company's ambitious financial projections.

Tevogen Bio's Innovative Approach and Financial Outlook

Tevogen Bio is leveraging AI-driven immunotherapy drug discovery to develop off-the-shelf, genetically unmodified precision T cell therapies 1

1

2

2

. The company's focus includes:

• Treating infectious diseases and cancers
• Addressing unmet needs of large patient populations
• Ensuring patient accessibility through advanced science and innovative business models

The company has reaffirmed its previously announced topline forecast, projecting:

• $1 billion in launch year for Tevogen Bio Oncology
• Nearly $1 billion for Tevogen Bio Specialty Care

Technological and Intellectual Property Assets

Tevogen Bio's approach to immunotherapy centers on harnessing CD8+ cytotoxic T lymphocytes, which the company describes as "one of nature's most powerful immunological weapons" 1

1

2

2

. The company's intellectual property portfolio includes:

• Three granted patents
• Nine pending US patents
• Twelve ex-US pending patents
• Two patents related to artificial intelligence

Challenges and Forward-Looking Statements

While Tevogen Bio's progress is promising, the company faces several challenges typical of the biotech industry:

1. Need for additional capital to execute its business plan
2. Potential legal proceedings
3. Rapidly evolving competitive landscape and technology
4. Regulatory hurdles and clinical trial uncertainties

The company's forward-looking statements acknowledge these risks and uncertainties, emphasizing that actual results may differ materially from projections 1

1

2

2

.

As Tevogen Bio continues to advance its AI-driven immunotherapy platform, the recognition of its CEO and strategic appointments signal the company's commitment to innovation and commercialization in the competitive landscape of personalized medicine and biotechnology.